{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=13", "query": { "condition": "Metastatic Solid Tumor Cancers", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1751, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T23:12:34.015Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02705105", "title": "Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Cancer", "Carcinoma", "Hepatocellular Carcinoma", "HCC" ], "interventions": [ { "name": "Mogamulizumab + Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-02", "completion_date": "2018-10-10", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Greenbrae, California • Los Angeles, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02705105" }, { "nct_id": "NCT02830724", "title": "Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Renal Cell Cancer", "Breast Cancer", "Melanoma", "Ovarian Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Anti-hCD70 CAR transduced PBL", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 124, "start_date": "2017-04-06", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02830724" }, { "nct_id": "NCT00003403", "title": "GPX-100 in Treating Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "GPX-100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gem Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-23", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Salt Lake City, Utah", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003403" }, { "nct_id": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "PEComa", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2017-01-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 1006, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834013" }, { "nct_id": "NCT05001282", "title": "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Endometrial Cancer", "Ovary Cancer", "Ovary Neoplasm", "Ovary Disease", "Ovary Metastasis", "Ovarian Diseases", "Ovarian Cancer Stage", "Ovarian Epithelial Cancer", "Ovarian Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Neoplasm Epithelial", "Ovarian Cancer Recurrent", "Endometrial Diseases", "Endometrial Adenocarcinoma", "Endometrial Carcinosarcoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrioid Adenocarcinoma", "Endometrial Neoplasms", "Endometrial Cancer Recurrent", "Endometrioid Tumor", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "ELU001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elucida Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-09-13", "completion_date": "2024-06-07", "has_results": false, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001282" }, { "nct_id": "NCT07405086", "title": "Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Renal Cell Carcinoma", "Metastatic Biliary Tract Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Immune Checkpoint Inhibitor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-04-24", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07405086" }, { "nct_id": "NCT03854227", "title": "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "PF-06939999 dose escalation", "type": "DRUG" }, { "name": "PF-06939999 monotherapy", "type": "DRUG" }, { "name": "PF-06939999 in combination with docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-03-14", "completion_date": "2022-04-27", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 22, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03854227" }, { "nct_id": "NCT06223542", "title": "Studying TAK-243 in Patients With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Indolent Non-Hodgkin Lymphoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "UAE Inhibitor TAK-243", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2025-03-24", "completion_date": "2027-04-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06223542" }, { "nct_id": "NCT04777994", "title": "Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor Cancer" ], "interventions": [ { "name": "ABBV-CLS-484", "type": "DRUG" }, { "name": "Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)", "type": "DRUG" }, { "name": "Programmed Cell Death-1 (PD-1) Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calico Life Sciences LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2021-03-09", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 15, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04777994" }, { "nct_id": "NCT06188702", "title": "S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MTAP-deleted Solid Tumors" ], "interventions": [ { "name": "S095035", "type": "DRUG" }, { "name": "TNG462", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Servier Bio-Innovation LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2024-04-29", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T23:12:34.015Z", "location_count": 5, "location_summary": "Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06188702" } ] }